文献速递生殖医学产科

癌症治疗是否损伤子宫并损害生育力?

Do cancer therapies damage the uterus and compromise fertility?
PubMed 文献 · Hum Reprod Update · 2020-01-01

该叙述性综述通过PubMed检索评估放疗或化疗后子宫维持健康妊娠的能力。现有文献存在重大局限,数据提示子宫可能遭受脱靶损伤,程度取决于癌症治疗类型和患者年龄;放疗或化疗暴露女性早产和低出生体重儿发生率更高。

要点

  • 青春期前接受腹部、盆腔或全身放疗的女孩子宫生长受限且对激素替代治疗抵抗。
  • 青春期后接受放疗的女性可从激素替代治疗获益,子宫体积和功能增加。
  • 放疗或化疗暴露女性早产和低出生体重儿发生率更高,即使卵巢功能正常或使用卵母细胞捐赠。

核心结论

  • 数据提示子宫可能遭受癌症治疗的脱靶损伤,损伤程度取决于癌症治疗类型和患者年龄,但现有文献存在重大局限,解释需谨慎。

研究设计与样本

  • 叙述性综述,通过PubMed(Medline)检索,关键词包括子宫、癌症幸存者、放疗、化疗、妊娠结局、生育力保存、不孕,未限制发表时间。

主要发现

  • 青春期前接受腹部、盆腔或全身放疗的女孩子宫生长受限且对激素替代治疗抵抗;青春期后接受放疗的女性可从激素替代治疗获益,表现为子宫体积和功能增加。
  • 既往接受放疗的女性移植冻存卵巢组织后未见活产报告,即使月经恢复;该技术对既往化疗女性是成功的生育力保存方法。
  • 放疗后维持足够卵巢功能的女性可自然妊娠,但分娩时子宫肌层薄和/或纤维化,危及安全分娩和后续妊娠。
  • 放疗或化疗暴露女性早产和低出生体重儿发生率更高,即使卵巢功能正常或使用卵母细胞捐赠。
  • 子宫损伤机制了解甚少,子宫肌层、血管系统和子宫内膜祖细胞可能是靶点,需进一步研究和良好对照的动物模型。

临床怎么用

  • 年轻女性需癌症治疗时,临床医生应提供准确信息以帮助就癌症治疗方案及有效生育力保存措施的开发和使用做出知情决策。

局限性

  • 原文明确述及当前可用文献存在重大局限,解释需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: As cancer survival rates improve, understanding and preventing the adverse off-target and long-term impacts of cancer treatments, including impacts on fertility, have become increasingly important. Cancer therapy-mediated damage to the ovary and depletion of the primordial follicle reserve are well characterised. However, our knowledge of the full extent of damage to the rest of the female reproductive tract, in particular the uterus, is limited. OBJECTIVE AND RATIONALE: Improving our understanding of the off-target effects of cancer therapies on the entire female reproductive tract is a critical step towards developing truly effective strategies to protect the fertility of cancer survivors. The objective of this narrative review was to critically evaluate the available literature regarding the capacity for the uterus to sustain a healthy pregnancy following exposure to radiotherapy or chemotherapy. SEARCH METHODS: The authors performed PubMed (Medline) searches using the following key words: uterus, cancer survivors, radiotherapy, chemotherapy, pregnancy outcome, fertility preservation, infertility. There were no limits placed on time of publication. OUTCOMES: Overall, there were major limitations to the current available literature, meaning that interpretations should be taken with caution. Despite these drawbacks, data suggest that the uterus may sustain off-target damage, with the extent of damage dependent on the type of cancer treatment and patient age. Specifically, uterine growth is stunted and resistant to hormone replacement therapy in prepubertal girls receiving abdominal, pelvic or whole-body radiotherapy. In contrast, females treated with radiotherapy post-puberty can benefit from hormone replacement therapy, as demonstrated by increased uterine volume and function. No live births have been reported in women previously exposed to radiotherapy after transplantation of cryopreserved ovarian tissue, even when menstruation returns. However, this technique has proven to be a successful fertility preservation method for women previously treated with chemotherapy. Obstetricians commonly report that women who maintain sufficient ovarian function can achieve pregnancy naturally following radiotherapy, but they have thin and/or fibrotic myometrium at delivery, compromising safe delivery and subsequent pregnancy. Furthermore, women exposed to either radiotherapy or chemotherapy have a higher prevalence of preterm birth and low birth weight infants, even in those with normal ovarian function or when oocyte donation is utilised. The mechanisms of potential uterine damage are poorly understood. While the myometrium, vasculature and endometrial progenitor cells are possibly targets, further studies are clearly required and well-controlled animal models could provide the best avenue for these types of future investigations. WIDER IMPLICATIONS: Female cancer survivors experience greater rates of early pregnancy loss and complications, suggesting that cancer therapy-induced damage to the uterus contributes to infertility. Despite clinical reports dating back to 1989, we highlight a surprising lack of detail in the literature regarding the precise nature and extent of off-target damage inflicted to the uterus in response to cancer therapies. Young women requiring cancer treatment, and the clinicians treating them, must be equipped with accurate information to aid informed decision-making regarding cancer treatment regimens as well as the development and use of effective fertility preservation measures. As the current literature on the impacts of cancer treatments is limited, we hope that our narrative review on this subject will stimulate more research in this important field.

来源:Hum Reprod Update,查看原文。版权归原作者所有。

引用

  1. Griffiths MJ, Winship AL, Hutt KJ, et al. Do cancer therapies damage the uterus and compromise fertility? Hum Reprod Update. 2020. PMID: 31863097. doi:10.1093/humupd/dmz041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。